Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

XH compiled/interpreted resources and was the primary author for majority of the manuscript. DL assisted with manuscript writing. YF assisted with manuscript edits. JZ and ZF developed the conception and overall design of the project/paper. JC and PW provided manuscript editing/revisions and interpretation of resources to include in the paper. All authors contributed to manuscript revision, and read and approved the submitted version.

Molecular probes targeting HER2 affibody can evaluate the expression status of tumor HER2 receptors and predict early efficacy after treatment, and significant progress has been made in the research on the integration of tumor diagnosis and treatment. The main applications of radionuclide-labeled HER2 molecular probes are summarized in Table 1 . Overview of the major applications of radionuclide-labeled HER2 affibody molecular probes. [ 111 In]: Indium-11 ( 111 In) is a pure γ-ray emitter with a half-life of 2.81 days, making it an ideal radionuclide tracer for SPECT imaging. Benzyl-dtpa,-CHX-A”-DTPA (diethylenetriaminepentaacetic acid) and DOTA (1,4,7,l0-tetraazacyclodo-decane- N,N,N,N -tetra acetic acid) have been used as chelating agents for affibody Z HER2:342. When labeled with 111 In, which showed a good labeling yield (>95%) and a high affinity (21-65 pM), the molecular probe with specific uptake by the SKOV3 ovarian cancer xenograft tumor tissues with high HER2 receptor expression showed high tumor targeting binding properties ( 48 – 52 ). Unfortunately, in addition to tumor uptake of these molecular probes, renal uptake is also high, increasing the potential for renal toxicity. Based on this disadvantage, Honarvar et al. ( 76 ) designed a 15-mer HP1 PNA recognition tag and a complementary HP2 hybridization probe 111 In-Z HER2:342 -SR-HP1 to reduce the uptake of the molecular probe in the kidney. Moreover, a number of studies have used DOTA as a chelating agent to bind to the affibodies Z HER2:342min , Z HER2:2395 , and Z HER2:2395 -Cys, and then labeled with the radionuclide 111 In. This method shows good potential for targeted imaging ( 77 – 80 ). However, one disadvantage of using DOTA as a chelator is that the liver uptake is relatively high. Researchers then compared the results of using DOTAGA (2-[1,4,7,10-Tetraazacyclododecane-4,7,10-tris(t-butyl acetate)]-pentanedioic acid-1t-butyl ester) instead of DOTA as a chelator, and found that the change improved the biodistribution of molecular probes in vivo , reducing uptake by the liver ( 81 ). [ 99m Tc]: Technetium-99m ( 99m Tc) emits γ-rays of 140 keV and has a half-life of 6.02 h. It can be obtained by the 99 Mo- 99m Tc generator and is inexpensive; therefore, it is widely used in clinical and basic research. An early study used the indirect labeling method to add chelating agent maGGG (mercaptoacetyl-glycyl-glycyl-glycyl) to the N-terminal of the affibody Z HER2:342 , and successfully labeled affibody Z HER2:342 with 99m Tc. The researchers further completed a series of in vivo biodistribution and imaging studies, and the results showed that the molecular probe was specifically absorbed by SKOV3 ovarian cancer xenograft tumor with high expression of the HER2 receptor and high targeting ability ( 79 ). However, the liver and gastrointestinal tract uptake of this molecular probe is high, thus affecting the detection rate of abdominal lesions. Subsequently, the research team replaced the chelating agent maGGG with maGSG (mercaptoacetyl-glycyl-seryl-glycyl), maG(D-S)G (mercaptoacetyl-glycyl-D-seryl-glycyl), and maSSS (mercaptoacetyl-seryl-seryl-seryl), respectively, and labeled it with 99m Tc. Results showed that when the glycine residue in the chelating agent maSSS was replaced with a hydrophilic serine amino group, the hydrophilic activity of the chelating agent maGGG was increased. Therefore, the uptake of the molecular probe in the liver and gastrointestinal tract was significantly reduced, resulting in a significant increase in the detection rate of abdominal tumor lesions. However, the excretion route was shifted from the liver to the kidney, increasing the potential for kidney toxicity ( 80 ). To overcome this shortcoming, the team further optimized the study design and compared the 99m Tc labeling studies using maGEG (mercaptoacetyl-Gly-Glu-Gly), maEEE (Mercaptoacetyl-Glu-Glu-G1u), maESE (mercaptoacetyl-glutamyl-seryl-glutamyl), maEES (mercaptoacetyl-glutamyl-glutamyl-seryl), maSEE (mercaptoacetyl-seryl-glutamyl-glutamyl), maSKS (mercaptoacetyl-seryl-lysyl-seryl), and maKKK (mercaptoacetyl-trilysyl) as chelators. The results showed that the use of the molecular probes 99m Tc-maEEE-Z HER2:342 , 99m Tc-maSKS-Z HER2:342 , and 99m Tc-maESE-Z HER2:342 with maEEE, maSKS, and maESE as chelators significantly reduced the radioactive uptake in the kidney. In addition, the radioactive uptake of 99m Tc- maESE-Z HER2:342 was found to be the most obvious, further improving the abdominal image quality ( 55 , 56 , 81 ). Furthermore, other studies introduced a chelating agent at the C-terminus or/and N-terminus of the affibody Z HER2:342 for 99m Tc labeling, and obtained molecular probes 99m Tc-(HE) 3 -Z HER2:342 -GGGC, 99m Tc-Z HER2:342 -GGGC, 99m Tc-Z HER2:V2 , etc. The researchers performed in vivo biodistribution and imaging studies, and results showed that these molecular probes are stable in vitro and in vivo , with high specificity and high targeting ( 82 – 84 ). [ 123 I/ 125 I]: Iodine-123 ( 123 I) has a half-life of 13.3 h and can emit 159 keV γ rays, which is suitable for SPECT imaging. 125 I has a long half-life (59.4 days) and is a convenient replacement nuclide usually used in the development of radioactive iodization technology instead of 123 I and 124 I ( 85 ). An early study used 125 I labeling for the affibody (Z HER2:4 )2, but SPECT imaging showed high radioactivity retention in the kidney and liver in addition to tumor uptake. This resulted in substandard image quality ( 86 ). To address the prevention of affibody destruction by radionuclides upon labeling, further studies were performed with iodobenzoate (PIB) and [4-isothiocyanate-amino]-undecahydro-o-dodecaborate (DABI) as chelators to label affibody molecule Z HER2:342 with 125 I, and molecular probes 125 I-PIB-Z HER2:342 and 125 I-DABI-Z HER2:342 were prepared. Results showed that 125 I-PIB-Z HER2:342 expressed high contrast imaging and low renal radioretention of HER2 in the mice bearing SKOV-3 xenografts; however, a disadvantage was that the molecular probe did not bind specifically to the tumor ( 44 , 87 ). Subsequently, the team used HPEM(4-hydroxyphenyl-ethyl-maleimide) as a chelating agent to design and synthesize the molecular probe 131 I/ 125 I-HPEM-Z HER2:342 -C. Compared with the previous molecular probe 125 I-PIB-Z HER2:342 , HPEM provided a site-specific conjugate for indirect radioiodination of cysteine-containing affibody Z HER2:342 , and preserved the specificity of binding to HER2-expressing cells ( 88 ). Several studies have shown that the labeling strategy of using HPEM as a chelator further reduces renal uptake, but increases hepatobiliary and gastric uptake; thus, this strategy is detrimental to the detection of abdominal metastases ( 85 , 87 , 88 ). To solve this problem, the HEHEHE sequence was recently introduced into the amino terminal of the affibody, and the molecular probe 125 I-PIB-(HE) 3 -G 3 was prepared by using PIB as a chelating agent. This process reduces the radioactive retention of the liver and kidney while maintaining the highly specific binding of tumor cells, and enables the obtainment of high contrast imaging of tumors expressing HER2 receptor in vivo ( 89 ). PET can provide molecular information such as function and metabolism, and has important clinical value in early diagnosis, staging and restaging of tumors, finding primary tumor or metastases, guiding tumor treatment, evaluating treatment efficacy, and predicting recurrence ( 90 ). Compared with SPECT imaging, PET imaging has the advantages of high spatial resolution, good sensitivity, and quantification ( 91 ). The radionuclide fluorine-18 ( 18 F), gallium-68 ( 68 Ga), copper-64 ( 64 Cu), rhenium-186/188 ( 186/188 Re), and other labeled HER2 affibodies have been used in preclinical research on ovarian cancer, showing good prospects for clinical application ( 54 , 67 , 68 , 78 , 92 – 97 ). [ 18 F]: The half-life of 18 F is 109.8 min, and the positron energy produced by 18 F is low (average of 0.25 MeV). Its annihilation distance in tissues is short (approximately 2.4 mm), which enables the obtainment of high-resolution images. Therefore, 18 F is considered as the most ideal nuclide for PET imaging. An early study used FBO (N-[4-flfluorobenzylidene]oxime) as a chelating agent to label the affibody Z HER2:477 to obtain the molecular probe 18 F-FBO-Z HER2:477 . The results of animal PET imaging showed that the molecular probe can specifically bind to the HER2 receptor in vitro and in vivo , and obvious radionuclide uptake can be seen in the SKOV3 tumor tissue. However, due to the large amount of radioactive retention in the liver and kidney, the molecular probe is not clinically applicable ( 94 ). Kramer-Marek et al. used N-[2-(4-fluoro-benzamido)ethyl] maleimide (FBEM) as a chelating agent to prepare the molecular probe 18 F-FBEM-Z HER2:342 , and animal PET imaging results showed that the molecular probe had high radiation uptake and high image contrast in mice bearing SKBR3 and SKOV-3 xenografts with high HER2 expression, but no obvious uptake in mice bearing MDA-MB-468 xenografts with low HER2 expression. However, the high radioactive uptake in the kidney and bone also limits its clinical application ( 67 ). Recently, researchers have used FET (fluoroethyl-L-tyrosine) as a linker to prepare a molecular probe [ 18 F]FET-Z HER2:342 , and a preclinical study has shown that the molecular probe specifically binds to tumors and has a lower radioactive uptake in the liver. Unfortunately, its radiochemical yield is relatively low ( 68 ). Moreover, different methods of 18 F labeling for Z HER2:2395 and Z HER2:2891 have been reported, but their clinical transformation has been hindered by a large amount of radioactive retention in the kidney or the complex manufacturing process and low yield of molecular probes ( 62 , 63 , 73 ). [ 68 Ga]: The half-life of 68 Ga is 68 min, and the positron decay rate is 89%. 68 Ga can be prepared by a 68 Ge- 68 Ga generator. It is suitable for labeling small molecules that can rapidly distribute in vivo and reach the target, and high-quality images can be obtained approximately 1 h after intravenous injection. An early animal study of PET imaging used DOTA as a chelating agent to label the HER2 affibody Z HER2:342 and the small-molecule protein MUT-DS of HER2, respectively, with 68 Ga ( 69 ). The results showed that the tumor tissue with high expression of HER2 receptor showed obvious radionuclide aggregation, which was quickly cleared in the blood, with low background and high image quality. However, the disadvantage was that there was also a high radioactive uptake in the kidney. Recently, a number of studies have successively used DOTA, NOTA (1,4,7-triazacyclononane- N,N,N -triacetic acid), and NODAGA [1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane] as chelating agents to label the affibodies Z HER2:S1 , Z HER2:2395 , and Z HER2:2891 , respectively, and performed molecular probe research in vivo and in vitro . The results showed that NODAGA as a chelator for 68 Ga-labeled synthesis of molecular probes provided the best tumor-to-organ ratio, and was the best chelator for 68 Ga-labeled HER2 affibody, indicating excellent prospects for clinical application ( 81 , 92 , 93 ). [ 64 Cu]: 64 Cu can simultaneously release β - with a maximum energy of 580 keV and β + with a maximum energy of 656 keV, which can be used for PET imaging and radionuclide therapy. The half-life of 64 Cu is 12.7 h, and it can be produced by nuclear reactors and medical accelerators ( 98 , 99 ). Researchers first used DOTA as a chelating agent to label the affibody Z HER2:477 with 64 Cu and performed PET imaging studies in tumor-bearing nude mice with high HER2 receptor expression. The results showed that the molecular probe can be significantly taken up by tumor tissue. However, the disadvantage is that there is also a large amount of aggregation in the liver and kidney, and the uptake of radioactivity in liver and kidney is significantly higher than that in tumor tissue, thus affecting the detection of abdominal lesions ( 100 ). Subsequently, the research team further introduced cysteine into different positions of the affibody Z HER2:342 for 64 Cu labeling to prepare molecular probes 64 Cu-DOTA-Cys-Z HER2:342 , 64 Cu-DOTA-Z HER2:342 (Cys39), and 64 Cu-DOTA-Z HER2:342 -Cys. All three probes showed good affinity and stability in in vitro studies, and 64 Cu-DOTA-Cys-Z HER2:342 had the highest affinity and in vivo stability. However, the problem of high renal radioactivity retention remained unresolved ( 72 ). In addition, some researchers conducted in vitro and in vivo studies and compared the use of NOTA and NODAGA as chelators for 64 Cu labeling of affibodies. The results showed that the tumor-to-organ ratio was higher when NODAGA was used as a chelator than when NOTA was used as a chelator. The disadvantage was that the molecular probes had higher radioactive retention in the kidney and bone marrow ( 101 ). Therefore, research of 64 Cu-labeled HER2 affibody molecular probe needs to be further optimized and perfected. [ 186/188 Re]: The two isotopes of rhenium, 186 Re and 188 Re, can simultaneously emit γ rays and β rays, enabling their use for both imaging and therapy. 186 Re is produced by the reactor and has a half-life of 3.72 days. 186 Re can emit β rays with a maximum energy of 1.08 MeV and γ rays with an energy of 155 keV at a time. 188 Re has a half-life of 17.0 h, can be produced by a 188 W/ 188 Re generator, and can emit β rays with a maximum energy of 2.1 MeV and γ rays with an energy of 137 keV. Orlova et al. ( 102 ) first used maGGG and maGSG as chelators to label affibody Z HER2:342 with 186 Re and compared the resulting molecular probe with the 99m Tc-labeled molecular probe. The results showed that the molecular probe 186 Re-maGSG-Z HER2:342 showed obvious radioactive uptake in the tumors of mice bearing SKOV3 xenografts at 4 h after injection. Compared with the 99m Tc-labeled molecular probe, the 186 Re-labeled molecular imaging probe significantly reduces the renal uptake; its renal uptake is only 1/4 of the 99m Tc-labeled molecular probe. However, the excretion of molecular probes through the hepatobiliary tract leads to relatively high uptake in the liver, which may affect the detection of liver lesions. Subsequently, the same research team attached different amino acid sequences to the carboxy-terminus to label the affibodies with 188 Re and compared them in vitro and in vivo . The results showed that the uptake of the molecular probe 188 Re-Z HER2:V2 with GGGC sequence linked to the carboxyl terminus was significantly higher than that of any organ tissue (including liver and kidney) at 4 h after injection. Furthermore, the uptake of the kidney was 5 times lower than that of the tumor, indicating that this molecular probe is a promising candidate for imaging and treatment of tumors with high expression of HER2 receptor ( 73 , 74 ). In addition, preclinical studies of PET molecular probes labeled to HER2 affibody by radionuclides such as astatine-211 ( 211 At), scandium-44 ( 44 Sc), zirconium-89 ( 89 Zr), and carbon-11 ( 11 C) through different chelating agents in SKOV3 ovarian tumors with high HER2 expression have also been reported in the literature, and the results show good potential for clinical application ( 103 – 106 ). Ovarian cancer is traditionally treated with radical tumor resection and platinum-paclitaxel chemotherapy. Most tumors eventually become resistant to cytotoxic chemotherapy, leading to disease recurrence and progression ( 107 ). Recent studies have shown significant efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with epithelial ovarian cancer, especially in patients with germline breast-related cancer antigens 1 and 2 (BRCA1/2) mutations. However, its clinical application value in patients without BRCA1/2 mutation remains controversial ( 108 – 110 ). The HER2 proto-oncogene is closely related to the occurrence of epithelial ovarian cancer; therefore, it provides an ideal target for the treatment of ovarian cancer. Trastuzumab, pertuzumab, olaparib, and lapatinib are widely approved by the Food and Drug Administration (FDA) for the treatment of HER2-positive cancers. However, clinical studies have shown that HER2-poszitive cancers are prone to become resistant to trastuzumab and pertuzumab; resistance mainly involves crosstalk with heterologous receptors, amplification, and the destruction of binding sites to HER2 receptors ( 111 , 112 ), which may be related to the abnormal activation of the PI3K-Akt signaling pathway leading to PI3KCA mutation, phosphatase, and tensin homologue loss ( 113 – 115 ). It is estimated that approximately half of patients with HER2-positive metastatic breast cancer do not respond to trastuzumab ( 116 ). Lapatinib has shown positive efficacy in patients with HER2-positive ovarian cancer, but its efficacy in patients with ovarian cancer is only 22% to 30% ( 117 , 118 ). Therefore, many researchers have recently focused on finding new methods and approaches for the comprehensive treatment of ovarian cancer through radioimmunotherapy. To date, many studies have focused on the targeted therapy of a variety of radionuclide-labeled HER2 affibody, including lutetium-177 ( 177 Lu), 64 Cu, and yttrium-90 ( 90 Y). Nevertheless, studies have shown that molecular probes of the radionuclide 64 Cu and 90 Y-labeled HER2 affibody need to be further optimized due to higher radioactive uptake in kidney or bone marrow and longer retention time ( 100 , 119 ). 177 Lu, with a half-life of 6.7 days, can emit β - particles with three energies of 498 keV (79.3%), 380 keV (9.1%), and 176 keV (12.2%). Due to its relatively low particle energy, the normal tissue around the lesion is less damaged, making it a very suitable radionuclide for therapy ( 120 ). In 2007, Tolmachev et al. first used CHX-A”-DTPA as a chelating agent to label affibody Z HER2:342 with 177 Lu; the results showed that 177 Lu-CHX-A”-DTPA-ABD-(Z HER2:342 )2 could prevent the growth of SKOV3 ovarian cancer cells highly expressing the HER2 receptor, compared with the control group injected with PBS and simultaneously injected with non-labeled affibody, 177 Lu-CHX-A”-DTPA-ABD-(Z HER2:342 )2 blocking group. The survival time of nude mice injected with 177 Lu-CHX-A”-DTPA-ABD-(Z HER2:342 )2 was significantly prolonged; however, a disadvantage of this affibody is the high radioactive retention in the blood and bone marrow ( 75 ). Subsequently, the researchers further linked high-affinity ABD035 to the N-terminus of the affibody Z HER2:2891 and linked a DOTA derivative maleimide group to the C-terminus, namely, Z HER2:2891 -ABD035-DOTA, and then labeled it with 177 Lu to obtain molecular probe 177 Lu-ABY-027. This was then compared with that of the previous molecular probe 177 Lu-CHX-A”-DTPA-ABD-(Z HER2:342 )2. The results showed that the uptake of the former in the tumor was twice that of the latter, and the radioactive retention in the liver and kidney was significantly reduced ( 75 ). To further improve the radioactive uptake of molecular probes by tumors and reduce the radioactive retention of normal organs such as the kidneys, the research team further optimized the molecular probes in a series of studies in which they conducted comparative evaluations in vivo and in vitro . The results showed that the molecular probe [ 177 Lu]Lu-HP16, containing 9 nucleic acid bases, has the highest tumor/kidney uptake ratio and is a promising molecular probe for targeted therapy of HER2-positive ovarian cancer ( 121 – 123 ). Although there are many advantages that make radionuclide-labeled HER2 affibodies particularly suitable for molecular imaging, many challenges and hurdles remain in the development of these affibodies. One disadvantage is that labeling methods can lead to increased lipophilicity, often leading to off-target interactions with normal tissues and binding to blood proteins ( 124 ). Another disadvantage may be the bacterial source of the protein scaffold, as repeated use in patient treatment leads to an increased risk of immunogenicity ( 125 ).

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

HER2 is found in the cytoplasm of normal cells, mainly in the mitochondrial cristae, with little amounts occurring on the cell membrane; HER2 is found only on the cell membrane in tumor cells. The expression of HER2 in normal ovarian epithelium is very low; however, the expression in epithelial ovarian tumor tissue has been reported to be high at 55 times that of normal ovarian epithelium ( 126 ). Epithelial ovarian cancer consists of histological subtypes, which include serous carcinoma (prevalence 75%), mucinous carcinoma (20%), endometrioid carcinoma (2%), and clear cell carcinoma (<1%). Regarding HER2 positivity, serous (29%) and mucinous carcinomas (38%) had higher positivity than endometrioid (20%) and clear cell carcinomas (23.1%), while the differential expressions of HER2 among different tissue types in epithelial ovarian carcinoma were important biomarkers for prognosis in epithelial ovarian cancer ( 127 ). Fluorodeoxyglucose (FDG) labeled with radionuclide 18 F is widely used in clinical practice and has been proved to be highly accurate in the differential diagnosis of benign and malignant ovarian masses ( 128 , 129 ). However, a study of 18 F-FDG PET/CT to evaluate the expression status of HER2 receptor has not been reported. Affibody has high affinity for HER2-expressing tumors, low molecular weight, stable biological activity, and fast blood clearance time ( 130 ). Recently, the use of molecular probes from radionuclide-labeled affibody has shown promise in tumor molecular imaging research. However, there are many difficulties in the preparation of molecular probes from radionuclide-labeled HER2 affibody that need to be addressed to enable more effective use in clinical practice. Most notably, research needs to focus on the reduction of non-specific uptake in the liver, kidney, bone marrow, and gastrointestinal tract. To this end, researchers have modified the amino acid sequence to change the molecular surface charge, lipid solubility, and affinity, and used different radionuclides to optimize the labeling method, improving the specific uptake of molecular probes at the tumor site, reducing the uptake of non-target organs, thereby optimizing the distribution in vivo . Moreover, different chelating agents have been introduced into the radionuclide labeling of HER2 affibody. Increasing the hydrophilicity of the chelating agent can reduce the non-specific uptake of the liver, enable the molecular probe to be excreted through the kidney, reduce the uptake of the gastrointestinal tract, and thus reduce the background of the image, increase the target/non-target ratio, and lead to an improved image. To date, more than 20 chelating agents have been introduced into molecular probes for radionuclide-labeled HER2 affibody. The advantages and disadvantages of commonly used chelators are shown in Table 2 . Overview of advantages and disadvantages of commonly used chelators as molecular probes. The median survival of patients with ovarian cancer has been significantly improved recently through the introduction of novel drug treatments and minimally invasive surgical techniques ( 22 ). However, the symptomatology, diagnosis, and treatment of ovarian cancer still pose great challenges. Multidisciplinary cooperation and multiple detection methods are needed to provide gynecological oncologists with as much detailed clinical data as possible to optimally design appropriate treatment plans for each patient ( 22 , 131 ). HER2 is overexpressed or amplified in various malignancies. Therefore, therapeutic drugs that target the linkage of HER2-positive tumor cells to a peptide with a high affinity for the HER2 receptor should be developed to target a variety of HER2-positive malignancies ( 132 ). To date, a variety of HER2-targeting therapeutic drugs have been developed, including HER2 addressing therapeutic monoclonal antibodies, nanobodies, and affibodies. Several of these drugs have entered the clinical trial stage, and the results of clinical studies have shown that they benefit patients with HER2-positive breast cancer. However, the study and use of radionuclide-labeled HER2 affibody have been hampered by its short residence time in the blood ( 133 ). In conclusion, the molecular probe of radionuclide-labeled HER2 affibody can accurately evaluate the expression status of HER2 receptor in epithelial ovarian cancer, which provides favorable conditions for the localization, diagnosis of cancer foci, targeted therapy, and prognosis evaluation. The research and development of new molecular probes for nuclear medicine aims to introduce radionuclides into cancer foci in a targeted manner, display systemic lesions, and kill tumor cells through radionuclides’ radioactivity. Continued progress will result in improved methods for the integration of the diagnosis and treatment of ovarian cancer. Nuclear medicine imaging technology is an important imaging method for basic and clinical research on malignant tumors. A variety of radionuclide-labeled HER2 affibody molecular probes have been successfully developed and have shown potential in preclinical experimental studies of ovarian cancer, laying a foundation for multi-center clinical trials. In the future, the research and development of HER2 affibody molecular probes will focus on optimizing the labeling method of radionuclides, using different chelating agents, or modifying the amino acid sequence to further improve the specific uptake of molecular probes in tumor sites, while reducing the uptake of non-target organs, especially in the liver, kidney, bone marrow, and gastrointestinal tract. This will optimize the distribution in the body, and the radionuclide-labeled HER2 small-molecule targeting binding protein can then be used in clinical practice as soon as possible to enable tumor-specific diagnosis, and to promote the evaluation of the therapeutic efficacy of targeted therapy drugs objectively at an early stage.

Ovarian cancer is the disease with the highest mortality rate after cervical cancer secondary to female reproductive tract malignant tumors; in 2020, 313,959 new patients with ovarian cancer and 207,252 new deaths from ovarian cancer were reported worldwide. Although ovarian cancer is generally more common in developed countries, studies have shown an increasing incidence in China ( 1 , 2 ). Several risk factors for ovarian cancer include genetics, reproduction, sex hormones, and lifestyle behaviors ( 3 ). Specifically, a family history of ovarian cancer in first- or second-degree relatives, polycystic ovary syndrome, endometriosis, gynecological inflammation, increased estrogen/androgen, high-fat diet, etc. are associated with a high risk of cancer. However, fertility, contraception including the intrauterine device and oral contraceptives, tubal ligation, and breastfeeding can reduce the risk of ovarian cancer ( 4 – 14 ). Ovarian cancer has an insidious onset and lacks specific clinical symptoms in the early stage, and the clinical diagnostic process is relatively unsatisfactory. Approximately 60% of patients with ovarian cancer are in the advanced stage of the disease by the time symptoms are recognized or medical help is sought. Therefore, the prognosis of patients is poor, with a 5-year survival rate of less than 30% ( 15 , 16 ).

Author YF was employed by Jiangsu Yuanben Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This study was funded by the National Natural Science Foundation of the People’s Republic of China, NSFC (grant number: 81571712), Zunyi Medical College Research Start Fund 2018ZYFY03, and QianKeHe platform talents [2017] (grant number: 5733-035).